OTHER FUNCTIONS NANOSORT"PHASE I, TOPIC 309, FLOWNOSTICS: PORTABLE MULTIPLEX ANA

癌症是一种复杂多样的疾病，其治疗可以通过更复杂的早期发现和监测来改进。NanoSort公司建议建立一个芯片实验室微流控设备平台，该平台可以检测和量化多达32种多路分析物，用于检测和监测血液或尿液样本中的癌症。这种新型的“FlowNostics”装置将利用32种按大小和颜色编码的微珠，这些微珠将通过阻抗和单个光学探测器相结合的方式进行检测，以检测单个激光激励的发射。NanoSort的FlowNostics平台将降低基于流式细胞术的多重分析的费用和复杂性，以增加接入和医疗诊断。 NanoSort的FlowNostics技术将改善公众健康，并通过改善对复杂分析的获取，帮助完成NIH和NCI的使命，而成本和复杂性仅为当前设备的一小部分。NanoSort的目标是使体检期间采集的常规血液样本能够报告癌症的存在，这将有助于癌症的早期发现，并在癌症达到晚期之前进行治疗。

Cancer is a complex and diverse disease whose treatment can be improved by more sophisticated early detection and monitoring. NanoSort, Inc. proposes to build a lab-on-a-chip microfluidic device platform that can detect and quantify up to 32 multiplexed analytes for the detection and monitoring of cancer from blood or urine samples. This novel "FlowNostics" device will utilize 32 kinds of microscopic beads, coded by their size and color, that will be detected by a combination of impedence and a single optical detector to detect emission from single laser excitation. NanoSort's FlowNostics platform will reduce the expense and complexity of flow cytometric-based multiplex assays to increase access and point-of-care diagnostics. NanoSort's FlowNostics technology will improve public health and help to fulfill the mission of the NIH and NCI by improving access to sophisticated analytics at a fraction of the cost and complexity of current devices. NanoSort's aim is to make routine blood samples taken during check-ups capable of reporting the presence of cancer, which will aid in the early detection of cancer and allow treatments before cancers have reached an advanced stage.